Mark Ainsworth
Researcher Next ID · RN-038965
Researcher · Biochemistry, Genetics and Molecular Biology
University of Southern Denmark
Odense, Denmark
- Works count
- 445
- Citation count
- 21,705
- H-index
- 74
- i10-index
- 224
Research interests
Publications
Clinical characteristics with inflammation profiling of long COVID and association with 1-year recovery following hospitalisation in the UK: a prospective observational study
The Lancet Respiratory Medicine · 2022 · https://doi.org/10.1016/s2213-2600(22)00127-8
A blood atlas of COVID-19 defines hallmarks of disease severity and specificity
Cell · 2022 · https://doi.org/10.1016/j.cell.2022.01.012
Azithromycin in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
The Lancet · 2021 · https://doi.org/10.1016/s0140-6736(21)00149-5
Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study
The Lancet Respiratory Medicine · 2021 · https://doi.org/10.1016/s2213-2600(21)00383-0
Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison
The Lancet Infectious Diseases · 2020 · https://doi.org/10.1016/s1473-3099(20)30634-4
Clinical Implications of Measuring Drug and Anti-Drug Antibodies by Different Assays When Optimizing Infliximab Treatment Failure in Crohn's Disease: Post Hoc Analysis of a Randomized Controlled Trial
The American Journal of Gastroenterology · 2014 · https://doi.org/10.1038/ajg.2014.106
Individualised therapy is more cost-effective than dose intensification in patients with Crohn’s disease who lose response to anti-TNF treatment: a randomised, controlled trial
Gut · 2013 · https://doi.org/10.1136/gutjnl-2013-305279
Tumor Necrosis Factor Inhibitors for Inflammatory Bowel Disease
New England Journal of Medicine · 2013 · https://doi.org/10.1056/nejmct1209614
Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel disease
Alimentary Pharmacology & Therapeutics · 2011 · https://doi.org/10.1111/j.1365-2036.2011.04682.x
Cut-off levels and diagnostic accuracy of infliximab trough levels and anti-infliximab antibodies in Crohn's disease
Scandinavian Journal of Gastroenterology · 2010 · https://doi.org/10.3109/00365521.2010.536254
Individual medicine in inflammatory bowel disease: Monitoring bioavailability, pharmacokinetics and immunogenicity of anti-tumour necrosis factor-alpha antibodies
Scandinavian Journal of Gastroenterology · 2009 · https://doi.org/10.1080/00365520802699278
Tumor Necrosis Factor-Alpha Binding Capacity and Anti-Infliximab Antibodies Measured by Fluid-Phase Radioimmunoassays as Predictors of Clinical Efficacy of Infliximab in Crohn's Disease
The American Journal of Gastroenterology · 2007 · https://doi.org/10.1111/j.1572-0241.2007.01638.x
Current projects
No projects listed.